Bristol-Myers Squibb Company (NYSE:BMY)went up by 0.29% from its latest closing price when compared to the 1-year high value of $63.69 and move down -33.33%, while BMY stocks collected +4.67% of gains with the last five trading sessions. MarketWatch.com reported 1 hour ago that 25 dividend stocks selected for value by an outperforming money manager

Bristol-Myers Squibb Company (NYSE:BMY) Worth an Investment?

Bristol-Myers Squibb Company (NYSE: BMY) scored price to earnings ratio above its average ratio, recording 12.55 times of increase in earnings at the present.

BMY Market Performance

BMY stocks went up by 4.67% for the week, with the monthly jump of 10.96% and a quarterly performance of 0.06%, while its annual performance rate touched -20.81%. The simple moving average for the period of the last 20 days is 4.08% for BMY stocks with the simple moving average of -1.45% for the last 200 days.

Analysts’ Opinion on Bristol-Myers Squibb Company (NYSE:BMY)

Many brokerage firms have already submitted their reports for BMY stocks, with Atlantic Equities repeating the rating for BMY shares by setting it to “Overweight”. The predicted price for BMY socks in the upcoming period according to Atlantic Equities is $63 based on the research report published on August 14, 2019.

Goldman, on the other hand, stated in their research note that they expect to see BMY stock at the price of $63. The rating they have provided for BMY stocks is “Buy” according to the report published on May 28, 2019.

Argus gave “ Hold” rating to BMY stocks, setting the target price at $63 in the report published on May 20, 2019.

BMY Stocks 4.08% Far from 50 Day Moving Average

After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, Bristol-Myers Squibb Company was unable to take a rebound, for now settling with -25.00% of loss for the given period.

The stock volatility was left at 2.32%, however, within the period of a single month, the volatility rate increased by 1.71%, while the shares surge at the distance of +10.50% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +1.92% upper at the present time.

In the course of the last 5 trading sessions, BMY went up by +4.67%, which changed the moving average for the period of 200 days to the total of -8.36% of losses for the stock in comparison to the 20-day moving average settled at $46.12. In addition, Bristol-Myers Squibb Company saw -8.10% in overturn over the period of a single year with a tendency to cut further losses.

BMY Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at Bristol-Myers Squibb Company (BMY), starting from BERTOLINI ROBERT J, who bought 11,000 shares at the price of $44.72 back on Jul 31. After this action, Rushing now owns 11,397 shares of Bristol-Myers Squibb Company, valued at $491,920 with the latest closing price.

Samuels Theodore R. II, the Director of Bristol-Myers Squibb Company, bought 5,000 shares at the value of $47.29 during a trade that took place back on May 16, which means that Samuels Theodore R. II is holding 27,000 shares at the value of $236,440 based on the most recent closing price.

BMY Stock Fundamentals

The current profitability levels are settled at +28.34 for the present operating margin and +71.25 for gross margin. The net margin for Bristol-Myers Squibb Company stands at +21.81. Total capital return value is set at 30.97, while invested capital returns managed to touch 25.63. Equity return holds the value 42.10%, with 15.60% for asset returns.

Based on Bristol-Myers Squibb Company (BMY), the company’s capital structure generated 52.38 points for debt to equity in total, while total debt to capital is set at the value of 34.37. Total debt to assets is settled at the value of 21.01 with long-term debt to equity ratio rests at 40.24 and long-term debt to capital is 26.41.

EBITDA value lies at +2.20 B with total debt to EBITDA carrying the value of 1.04. The value for Enterprise to Sales is 3.16 with debt to enterprise value settled at 0.09. The receivables turnover for Bristol-Myers Squibb Company is 3.96 with the total asset turnover at the value of 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.61.